Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis & Rheumatology 2026 Open access

Read full text
Authors: Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati
+3 more Anabela Cardoso, Mark C. Genovese, Alexis Ogdie
DOI: 10.1002/art.70134
Cited by: 25
References: 46

Abstract

OBJECTIVE: Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight-related comorbidity or obesity. METHODS: TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to

Fields of Study & Subjects

Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Arthritis & Rheumatology
Publisher
Wiley
Publication date
28 March 2026
Language
EN